At the news
? BEARISHIMPACT 8/10 8-K filed Mar 3, 2026 at 08:35 ET
Theravance Biopharma's Phase 3 CYPRESS study for ampreloxetine failed to meet its primary endpoint, prompting the company to wind down the program. In response, the company is restructuring, cutting costs by ~60% ($70M), reducing its workforce by ~50%, and accelerating a strategic review that could include a sale. Despite the setback, the company maintains a strong cash position (~$400M expected) and a profitable commercial product, YUPELRI.
- Phase 3 CYPRESS study for ampreloxetine failed to meet primary endpoint (OHSA Composite Score).
- Company is winding down the ampreloxetine program and its entire R&D function.
- Organizational restructuring will reduce operating expenses by ~60% (~$70 million) and impact ~50% of the workforce.
- Strategic Review Committee is accelerating its review of alternatives to maximize shareholder value, including a potential sale of the company.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access